Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quince Therapeutics, Inc.

1.40
+0.07505.68%
Volume:227.96K
Turnover:312.35K
Market Cap:63.43M
PE:-1.00
High:1.41
Open:1.31
Low:1.30
Close:1.32
Loading ...

BRIEF-Quince Therapeutics announces closing of up to $22 million private placement of securities

Reuters
·
19 Jun

Quince Therapeutics Secures $22 Million in Private Placement to Support Phase 3 Clinical Trials and Pipeline Expansion

Reuters
·
19 Jun

Quince Therapeutics Announces Closing of up to $22 Million Private Placement of Securities

THOMSON REUTERS
·
19 Jun

Quince Therapeutics Inc. Announces $11.5 Million Private Placement, CEO Dirk Thye Purchases $200K in Shares

Reuters
·
14 Jun

BRIEF-Quince Therapeutics Announces Pricing Of Up To $22 Mln Private Placement Of Securities

Reuters
·
13 Jun

Quince Therapeutics Secures Up to $22 Million in Private Placement to Advance Rare Disease Treatments

Reuters
·
13 Jun

Quince Therapeutics Inc - Financing to Provide $11.5 Mln Upfront, $10.4 Mln From Warrants

THOMSON REUTERS
·
13 Jun

Quince Therapeutics Announces Pricing of up to $22 Million Private Placement of Securities

THOMSON REUTERS
·
13 Jun

Quince Therapeutics Inc - Proceeds Expected to Fund Operations Into Second Quarter 2026

THOMSON REUTERS
·
13 Jun

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA)

TIPRANKS
·
08 Jun

Quince Therapeutics Inc. Held Annual Stockholder Meeting Online

Reuters
·
06 Jun

Quince Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
04 Jun

Quince Therapeutics Says Enrollment for Phase 3 Clinical Trial in Ataxia-Telangiectasia Exceeds 75%

MT Newswires Live
·
04 Jun

Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial

TIPRANKS
·
04 Jun

Quince Therapeutics Granted FDA Fast Track Designation for eDSP System in Treating Ataxia-Telangiectasia

Reuters
·
04 Jun

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 Neat Clinical Trial in Ataxia-Telangiectasia

THOMSON REUTERS
·
04 Jun

Maxim Group Sticks to Its Buy Rating for Quince Therapeutics (QNCX)

TIPRANKS
·
15 May

Quince Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Quince Therapeutics Inc - Plans Early Enrollment Conclusion for Phase 3 Neat Trial - SEC Filing

THOMSON REUTERS
·
13 May

Quince Therapeutics Inc - Reports $15 Million Net Loss, $0.34 per Share for Q1 2025 - SEC Filing

THOMSON REUTERS
·
13 May